President & CEO
I am the President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). My responsibilities include leading the team that develops new products and brings them to market, as well as creating strategic plans for the company’s product portfolio to ensure development programs meet quality and safety standards required by medical and regulatory agencies.
Since my appointment in 2010, I have led the development efforts of compounds in neuroscience, cardio-renal, and oncology, and was instrumental in the development and registration of ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension. I also helped guide the development and registration of SAMSCA® (tolvaptan), marking the first time Otsuka successfully developed and commercialized a product entirely on its own in the U.S.
I joined Otsuka in 2002 as a board-certified psychiatrist and served as OPDC’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During my career at Otsuka—and earlier at Bristol-Myers Squibb (BMS)—I was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole), which Otsuka marketed in collaboration with BMS.
I received an A.B. degree in history and science from Harvard University and an M.D. degree from Case Western Reserve University.